Cytokinetics EBIT Growth
The Year-over-Year EBIT Growth of Cytokinetics (CYTK) as of Nov 6, 2026 is -31.55 %. In the previous year, Year-over-Year EBIT Growth was -11.95 % — a change of 163.91% (lower).
Get this data via API
Financial Data API
EBIT Growth
-31.55 %
YoY
163.91%
Last updated:
The Cytokinetics EBIT Growth history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT Growth | YoY |
|---|---|---|
| -31.55 % | +163.91% | |
| -11.95 % | -71.45% | |
| -41.87 % | -52.09% | |
| -87.39 % | -11.12% | |
| -98.33 % | -2,074.24% | |
| 4.98 % | -144.50% | |
| -11.19 % | -151.84% | |
| 21.59 % | -103.05% | |
| -706.82 % | -571.35% | |
| 149.96 % | -197.67% | |
| -153.54 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cytokinetics Stock analysis
Frequently Asked Questions about Cytokinetics stock
Year-over-Year EBIT Growth of Cytokinetics is -31.55 % in 2025.
On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Cytokinetics since 2006 – with annual values, charts, and detailed analysis.
EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.
To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.
Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Cytokinetics historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Growth — Cytokinetics
All Key Metrics — Cytokinetics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth